GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oramed Pharmaceuticals Inc (STU:OJU1) » Definitions » Cyclically Adjusted Revenue per Share

Oramed Pharmaceuticals (STU:OJU1) Cyclically Adjusted Revenue per Share : €0.14 (As of Mar. 2025)


View and export this data going back to 2007. Start your Free Trial

What is Oramed Pharmaceuticals Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Oramed Pharmaceuticals's adjusted revenue per share for the three months ended in Mar. 2025 was €0.045. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.14 for the trailing ten years ended in Mar. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Oramed Pharmaceuticals was 28.90% per year. The lowest was -2.30% per year. And the median was 4.90% per year.

As of today (2025-05-28), Oramed Pharmaceuticals's current stock price is €1.878. Oramed Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was €0.14. Oramed Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 13.41.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Oramed Pharmaceuticals was 232.50. The lowest was 13.86. And the median was 47.14.


Oramed Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Oramed Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oramed Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Oramed Pharmaceuticals Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.12 0.12 0.13 - -

Oramed Pharmaceuticals Quarterly Data
May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 0.14

Competitive Comparison of Oramed Pharmaceuticals's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Oramed Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oramed Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oramed Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Oramed Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


;
;

Oramed Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Oramed Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.045/134.9266*134.9266
=0.045

Current CPI (Mar. 2025) = 134.9266.

Oramed Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201505 0.000 100.333 0.000
201508 0.000 100.548 0.000
201511 0.000 100.135 0.000
201602 0.009 100.040 0.012
201605 0.011 101.355 0.015
201608 0.024 101.617 0.032
201611 0.043 101.829 0.057
201702 0.043 102.779 0.056
201705 0.042 103.256 0.055
201708 0.039 103.587 0.051
201711 0.037 104.072 0.048
201802 0.034 105.052 0.044
201805 0.036 106.148 0.046
201808 0.033 106.383 0.042
201811 0.034 106.338 0.043
201902 0.034 106.649 0.043
201905 0.035 108.048 0.044
201908 0.035 108.245 0.044
201911 0.035 108.519 0.044
202002 0.035 109.139 0.043
202005 0.027 108.175 0.034
202008 0.024 109.662 0.030
202011 0.024 109.793 0.029
202102 0.020 110.968 0.024
202105 0.019 113.576 0.023
202108 0.018 115.421 0.021
202111 0.016 117.269 0.018
202203 0.016 121.301 0.018
202206 0.016 125.017 0.017
202209 0.018 125.227 0.019
202212 0.016 125.222 0.017
202303 0.016 127.348 0.017
202306 0.015 128.729 0.016
202309 0.000 129.860 0.000
202312 0.000 129.419 0.000
202403 0.000 131.776 0.000
202406 0.000 132.554 0.000
202409 0.000 133.029 0.000
202412 0.000 133.157 0.000
202503 0.045 134.927 0.045

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Oramed Pharmaceuticals  (STU:OJU1) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Oramed Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1.878/0.14
=13.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Oramed Pharmaceuticals was 232.50. The lowest was 13.86. And the median was 47.14.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Oramed Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Oramed Pharmaceuticals's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Oramed Pharmaceuticals Business Description

Industry
Traded in Other Exchanges
Address
1185 Avenue of the Americas, Third Floor, New York, NY, USA, 10036
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.

Oramed Pharmaceuticals Headlines

No Headlines